Castel V - Search Results

1

Intra-Tumour Genetic Heterogeneity and Prognosis in High-Risk Neuroblastoma.

López-Carrasco A, Berbegall AP, Martín-Vañó S, Blanquer-Maceiras M, Castel V, Navarro S, Noguera R. López-Carrasco A, et al. Among authors: castel v. Cancers (Basel). 2021 Oct 15;13(20):5173. doi: 10.3390/cancers13205173. Cancers (Basel). 2021. PMID: 34680323 Free PMC article.

2

The treatment of advanced neuroblastoma. Results of the Spanish Neuroblastoma Study Group (SNSG) studies.

Castel V, García-Miguel P, Melero C, Navajas A, Navarro S, Molina J, Badal MD, Ruiz-Jimenez JI. Castel V, et al. Eur J Cancer. 1995;31A(4):642-5. doi: 10.1016/0959-8049(95)00072-q. Eur J Cancer. 1995. PMID: 7576986 Clinical Trial.

3

Study of bcl-2 protein expression and the apoptosis phenomenon in neuroblastoma.

Mejia MC, Navarro S, Pellin A, Castel V, Llombart-Bosch A. Mejia MC, et al. Among authors: castel v. Anticancer Res. 1998 Mar-Apr;18(2A):801-6. Anticancer Res. 1998. PMID: 9615722

4

Expression of type I interferon receptor and its relation with other prognostic factors in human neuroblastoma.

Mejía C, Navarro S, Colamonici OR, Pellín A, Castel V, Llombart-Bosch A. Mejía C, et al. Among authors: castel v. Oncol Rep. 1999 Jan-Feb;6(1):149-53. Oncol Rep. 1999. PMID: 9864419

5

Prospective evaluation of the International Neuroblastoma Staging System (INSS) and the International Neuroblastoma Response Criteria (INRC) in a multicentre setting.

Castel V, García-Miguel P, Cañete A, Melero C, Navajas A, Ruíz-Jiménez JI, Navarro S, Badal MD. Castel V, et al. Eur J Cancer. 1999 Apr;35(4):606-11. doi: 10.1016/s0959-8049(98)00395-5. Eur J Cancer. 1999. PMID: 10492635

6

Angiogenesis in neuroblastoma: relationship to survival and other prognostic factors in a cohort of neuroblastoma patients.

Cañete A, Navarro S, Bermúdez J, Pellín A, Castel V, Llombart-Bosch A. Cañete A, et al. Among authors: castel v. J Clin Oncol. 2000 Jan;18(1):27-34. doi: 10.1200/JCO.2000.18.1.27. J Clin Oncol. 2000. PMID: 10623690

7

Outcome of high-risk neuroblastoma using a dose intensity approach: improvement in initial but not in long-term results.

Castel V, Cañete A, Navarro S, García-Miguel P, Melero C, Acha T, Navajas A, Badal MD. Castel V, et al. Med Pediatr Oncol. 2001 Dec;37(6):537-42. doi: 10.1002/mpo.1248. Med Pediatr Oncol. 2001. PMID: 11745893 Clinical Trial.

8

Molecular biology of neuroblastoma.

Castel V, Grau E, Noguera R, Martínez F. Castel V, et al. Clin Transl Oncol. 2007 Aug;9(8):478-83. doi: 10.1007/s12094-007-0091-7. Clin Transl Oncol. 2007. PMID: 17720650 Review.

9

Epigenetic alterations in disseminated neuroblastoma tumour cells: influence of TMS1 gene hypermethylation in relapse risk in NB patients.

Grau E, Martinez F, Orellana C, Canete A, Yañez Y, Oltra S, Noguera R, Hernandez M, Bermúdez JD, Castel V. Grau E, et al. Among authors: castel v. J Cancer Res Clin Oncol. 2010 Sep;136(9):1415-21. doi: 10.1007/s00432-010-0796-9. Epub 2010 Feb 7. J Cancer Res Clin Oncol. 2010. PMID: 20140741

10

Comparative study of MLPA-FISH to determine DNA copy number alterations in neuroblastic tumors.

Villamón E, Piqueras M, Berbegall AP, Tadeo I, Castel V, Navarro S, Noguera R. Villamón E, et al. Among authors: castel v. Histol Histopathol. 2011 Mar;26(3):343-50. doi: 10.14670/HH-26.343. Histol Histopathol. 2011. PMID: 21210347

Save citations to file

Email citations

Send citations to clipboard

Add to Collections

Add to My Bibliography

Create a file for external citation management software

Your saved search

Your RSS Feed

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

168 results

Search Page